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ABSTRACT
A UK-wide database of structured asthma review
consultations was used to investigate the prevalence of
‘off-label’ anti-asthma prescriptions in relationship to
clinical symptoms of asthma control. The 1050 children
(6.1%) aged 16 years or under issued with an off-label
prescription reported more nighttime, daytime and
activity asthma symptoms, and used more short-acting
β2-agonist medication than their peers. Off-label
prescribing for children with asthma in UK primary care
is associated with worse levels of self-reported asthma
control.
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INTRODUCTION
One in 10 people in the UK will receive an anti-
asthma prescription at some stage in their
childhood.1 Asthma management guidelines give
specific advice on medications and associated
doses to be used for children, but make allowances
for consultant paediatricians to increase these
doses.2 ‘Off-label’ prescribing in hospitals is a
commonly accepted practice,3 as the advantages of
disease control out-weigh the theoretical risk of
harm.4
The majority of patients with asthma are managed
exclusively within general practice. Primary care
health professionals have developed the skills to
manage moderate-to-severe asthma, and are
familiar with prescribing a wide range of medication
products and medication.5 GPs face the same off-
label prescribing dilemma, with the National Service
Framework for Children, Young People and Maternity
Services6 suggesting that prescribing of unlicensed
and off-label medications should be considered to
manage disease, but only where local standards and
arrangements are in place to oversee and monitor
the process.
Off-label prescribing is expanding in primary care,
with reported levels between 13–29%.7–10 There has
been little work relating off-label prescribing to
clinical symptoms for large populations. The clinical
circumstances in which off-label prescribing occurs
need to be investigated to inform the debate over the
use of off-label medication.
METHOD
General practices throughout the UK were invited to
participate in an audit process. Practices invited
patients receiving preventative asthma medication
for review, as recommended by guidelines for
asthma management.2 The structured clinical review
was guided by and recorded using specially
designed software based on a well-established
standardised recording tool.11 Practices recorded
review consultations for varying periods of time
between August 2001 and December 2004.
The review addressed inhaler technique, self-
management plan use, compliance, education, and
therapeutic change. Data recorded were presence of
symptoms, level of asthma control, health service
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utilisation and medication. Data from patients who
gave written consent were anonymised and returned
to the University of Dundee for analysis and
preparation of audit feedback to practices.
The British National Formulary (March 2003) was
searched for age-related restrictions for asthma
medications. An off-label prescription was identified
as a formulation not licensed for use in children, not
licensed for use in a particular age group, or with a
specific dosage not licensed for use. The database
was analysed and all recorded consultations for
patients aged 16 years and under were extracted.
Medication use at each consultation was examined
and patients receiving an off-label prescription were
identified.
Details of the first recorded consultation for each
patient were extracted: age, sex, symptom scores at
night, daytime and during activity, daily use of short-
acting β2-agonists, recorded compliance, and poor
inhaler technique.
Statistical analysis
To test for differences in proportions for patients in
each category of interest, χ2 tests were performed
and presented as the χ2 test statistic, degrees of
freedom and P-value. The χ2 test for trend was
reported when it was significant.
RESULTS
A total of 1188 practices returned data on 17 163
children aged 16 years or under; 9800 (57.1%) were
male. Of these children 1050 (6.1%) received an off-
label prescription, 325 (1.9%) received drugs not
licensed for their age group, and 767 (4.5%) received
drugs at a higher than recommended dosage. Anti-
cholinergics, oral β2-agonists, long-acting β2-
agonists, inhaled corticosteroids and combinations
of long-acting β2-agonists and inhaled
corticosteroids, were prescribed outside their
licensed age groups, and at doses different from
those recommended.
Younger children were more likely to have an off-
label prescription (Table 1). The sex distribution was
unremarkable.
Off-label prescriptions were associated with
increases in the level of symptoms at nighttime,
daytime and during activity, and reported daily short-
acting β2-agonist use, but not with compliance or
inhaler technique (Table 2).
DISCUSSION
This study suggests an association among off-label
prescribing, higher levels of symptoms, and more
frequent use of short-acting β2-agonists. GPs appear
to be prescribing off-label medication to help
manage more poorly controlled asthma in children.
How this fits in
Previous research has shown high levels of ‘off-label’ prescribing to
hospital-based paediatric populations. More recent studies have shown similar
findings in community settings. This study of patients attending practices
throughout the UK shows a relationship between instances of off-label
prescribing and increased symptoms of asthma and reliever medication use.
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Children with Off-label χ2 test
licensed prescription for trenda
prescribing (%) (%) (P-value)
Total number of children 16 113 1050
Males 9198 (57.1) 602 (57.3) 0.016
Females 6915 (42.9) 448 (42.7) (0.900)
Age in years
0–2 452 (2.8) 89 (8.5)
3–5 2190 (13.6) 266 (25.3) 81.885
6–11 7867 (48.5) 353 (33.5) (<0.001)
12–16 5548 (34.5) 340 (32.4)
Fifty-eight patients (two with ‘off-label’ prescriptions) did not have a valid age recorded.
aDegrees of freedom = 1.
Table 1. Distribution of sex and age by off-label prescribing.
Children with χ2 test
licensed Off-label for trenda
prescribing (%) prescription (%) (P-value)
Total number of children 16 113 1050
Nighttime symptom scoreb
0 — None 8959 (55.6) 403 (38.4)
1 — 1–2 per month 2510 (15.6) 202 (19.2) 126.705
2 — 1–2 per week 2377 (14.8) 196 (18.7) (<0.001)
3 — Daily 2267 (14.1) 249 (23.7)
Daytime symptom scoreb
0 — None 6649 (41.3) 301 (28.7)
1 — 1–2 per month 3382 (21.0) 208 (19.8) 105.346
2 — 1–2 per week 3236 (20.1) 239 (22.8) (<0.001)
3 — Daily 2846 (17.7) 302 (28.8)
Activity symptom scoreb
0 — Rarely 6925 (43.0) 347 (33.0)
1 — Sport 5919 (36.7) 361 (34.4) 87.082
2 — Active play 2876 (17.8) 293 (27.9) (<0.001)
3 — Walking on flat 393 (2.4) 49 (4.7)
Daily short acting β2-agonist useb
0 9536 (59.2) 467 (44.5)
1 2014 (12.5) 132 (12.6) 93.105
2 2319 (14.4) 221 (21.0) (<0.001)
>3 2244 (13.9) 230 (21.9)
Poor compliance as assessed 1.518
by the reviewer 3200 (19.9) 208 (19.8) (0.218)
Poor inhaler technique as 0.116
observed at the review 1735 (10.8) 109 (10.4) (0.733)
aDegrees of freedom = 1. bSignificantly higher for patients who received an off-label
prescription.
Table 2. Symptom scores, short acting β2-agonist use,
compliance and inhaler technique by off-label prescribing
characteristics.
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However, this study cannot comment on whether
local standards and monitoring arrangements are
established as recommended by the National
Service Framework for Children, Young People and
Maternity Services.6 It is important to state that all
therapeutic decisions involve risk–benefit analysis,
not just those involving off-label medications.
The study prevalence of 6% is lower than the
figure of 26% reported by Ekins-Daukes et al,7 but is
similar in that high dosages are the main cause of off-
label prescribing in anti-asthma medications.
Although prevalence estimates vary between
studies, the same conclusion is drawn; all clinicians
working in primary care will encounter the dilemma
of seeking optimum control within the constraints of
prescribing guidelines.
Although based on ‘real life’ clinical practice the
current study has limitations because the clinicians
who chose to participate in an electronic review and
feedback service are by definition atypical. However,
the children under their care are likely to be
representative of children with asthma in the UK. It
may be that trained or ‘asthma interested’ GPs are
less willing to advocate off-label prescribing for
uncontrolled asthma effecting the rate. However, the
converse might equally be true. Further research
including a qualitative examination of views and
attitudes to off-label prescribing among GPs could
be helpful in determining why the decision to
prescribe is made.
This study suggests that off-label prescribing in
children with asthma occurs in those with the
poorest asthma control. Each individual case
requires a prescribing decision which involves
prescriber and patient in a risk–benefit analysis.
Further work is required to fully understand this
decision making process.
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